{
  "main_header": {
    "sid": 10039622,
    "name": "Influx Health.",
    "stock_name": "Influx Health.",
    "full_name": "Influx Healthtech Ltd",
    "name_url": "stocks-analysis/influx-health",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "240.00",
    "chg": -2.05,
    "chgp": "-0.85%",
    "dir": -1,
    "prev_price": "242.05",
    "mcapval": "567.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "INFLUX",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0MYZ01012",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 60600,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/influx-health-10039622-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Influx Health. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-influx-health-overvalued-or-undervalued-3745749",
        "imagepath": "",
        "date": "2025-12-04 08:51:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Understanding Influx Health’s Valuation Metrics</strong></p>\n<p>Influx Health trades at a price-to-earnings (PE) ratio exceeding 40, which is notably higher than many of its pharmaceutical peers. This elevated PE ratio suggests that investors are pricing in strong future earnings growth or premium quality in the company’s business model. The price-to-book value stands near 6, indicating that the market values the company at nearly six times its net asset value, a sign of confidence in its intangible assets or growth prospects.</p>\n<p>Enterprise value multiples such as EV to EBIT and EV to EBITDA are also elevated, at around 28 and 24 respectively. These figures imply that the market is willing to pay a premium for Influx Health’s earnings before interest, taxes, depreciation, and amortisatio..."
      },
      {
        "title": "How has been the historical performance of Influx Health.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-influx-health-3695915",
        "imagepath": "",
        "date": "2025-11-13 00:45:11",
        "description": "Answer:\nThe historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.\n\nBreakdown:\nInflux Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased f..."
      }
    ],
    "total": 2,
    "sid": "10039622",
    "stock_news_url": "https://www.marketsmojo.com/news/influx-healthtech-10039622"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Influx Health. overvalued or undervalued?

2025-12-04 08:51:50

Understanding Influx Health’s Valuation Metrics

Influx Health trades at a price-to-earnings (PE) ratio exceeding 40, which is notably higher than many of its pharmaceutical peers. This elevated PE ratio suggests that investors are pricing in strong future earnings growth or premium quality in the company’s business model. The price-to-book value stands near 6, indicating that the market values the company at nearly six times its net asset value, a sign of confidence in its intangible assets or growth prospects.

Enterprise value multiples such as EV to EBIT and EV to EBITDA are also elevated, at around 28 and 24 respectively. These figures imply that the market is willing to pay a premium for Influx Health’s earnings before interest, taxes, depreciation, and amortisatio...

Read More

How has been the historical performance of Influx Health.?

2025-11-13 00:45:11

Answer: The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025. Breakdown: Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased f...

Read More

View All News